Comparing Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) & Marker Therapeutics (NASDAQ:MRKR)

Marker Therapeutics (NASDAQ:MRKR) and Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Profitability

This table compares Marker Therapeutics and Rock Creek Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-304.56%	-92.35%	-75.73%
Rock Creek Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Marker Therapeutics and Rock Creek Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	0	3	3	3.14
Rock Creek Pharmaceuticals	0	0	0	0	0.00

Marker Therapeutics presently has a consensus target price of $10.17, indicating a potential upside of 608.48%. Given Marker Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Rock Creek Pharmaceuticals.

Insider and Institutional Ownership

22.4% of Marker Therapeutics shares are held by institutional investors. 7.8% of Marker Therapeutics shares are held by company insiders. Comparatively, 0.9% of Rock Creek Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Marker Therapeutics and Rock Creek Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$6.59 million	3.63	-$10.73 million	($1.23)	-1.17
Rock Creek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Rock Creek Pharmaceuticals has lower revenue, but higher earnings than Marker Therapeutics.

Summary

Marker Therapeutics beats Rock Creek Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

About Rock Creek Pharmaceuticals

Rock Creek Pharmaceuticals, Inc. is an early stage life science company, which engages in the discovery, development, and commercialization of new drugs, formulations, and compounds that provide therapies for chronic and acute inflammatory diseases. It focuses on small molecule therapeutics that exhibit anti-inflammatory pharmacological characteristics. The company was founded by Jonnie R. Williams, Sr. on June 24, 1985 and is headquartered in Sarasota, FL.